Skip to main content
Premium Trial:

Request an Annual Quote

Migrations: Feb 27, 2009

Premium

Fate Therapeutics announced this week that Rudolf Jaenisch, founding member of the Whitehead Institute for Biomedical Research and a professor of biology at the Massachusetts Institute of Technology, has joined the company's team of scientific founders.

In connection with the appointment, Fate Therapeutics also announced this week that it has completed an exclusive license agreement with the Whitehead Institute covering discoveries in the area of cell reprogramming.

Jaenisch is a founding member of the Whitehead Institute. He has coauthored more than 300 research papers, is a member of the National Academy of Sciences, and has received awards including the First Peter Gruber Foundation Award in Genetics (2001), Robert Koch Prize for Excellence in Scientific Achievement (2002), Brupbacher Foundation Cancer Award (2003), Vilcek Prize (2007), and Massry Prize (2008).


Bio-Matrix Scientific Group announced this week that it has named Feng Lin and Marilyn Panahi to the newly created positions of laboratory/scientific director and quality assurance director, respectively.

Lin was previously a senior research scientist for R&D at Inovio Biomedical.

Prior to joining Bio-Matrix, Panahi was quality manager for Therapheresis.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.